Lv1
20 积分 2023-12-06 加入
Interstitial Lung Disease
6小时前
待确认
The effect of metformin in EML4-ALK+ lung cancer alone and in combination with crizotinib in cell and rodent models
29天前
已完结
Non-small-cell lung cancer
2个月前
已完结
P3.08F.01 Interim Analysis of a Phase 2 Prospective Trial of Induction Lorlatinib in Locally Advanced ALK-Positive NSCLC (LORIN)
2个月前
已关闭
Interstitial lung disease risk of anaplastic lymphoma kinase tyrosine kinase inhibitor treatment of non-small cell lung cancer: a real-world pharmacovigilance study
4个月前
已完结
Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology
4个月前
已完结
ALK in cancer: from function to therapeutic targeting
4个月前
已完结
EP.12B.14 Platinum-Pemetrexed Chemotherapy and Lorlatinib Combination in Advanced ALK Positive NSCLC Progressing to Lorlatinib: A Case Series
5个月前
已关闭
EP.12B.14 Platinum-Pemetrexed Chemotherapy and Lorlatinib Combination in Advanced ALK Positive NSCLC Progressing to Lorlatinib: A Case Series
5个月前
已关闭
Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease
5个月前
已完结
皖公网安备34019202002308
